Nacuity Pharmaceuticals is conducting the SLO-RP Study Phase 1/2 clinical trial of their proprietary NPI-001 Tablets, an antioxidant drug. The study will examine the safety and efficacy of these oral NPI-001 Tablets compared to placebo tablets for participants who have vision loss due to retinitis pigmentosa (RP) with Usher syndrome. The study takes place over the course of 24 months. This study is expected to be completed in September 2023.
Nacuity Related Science News